1. Tremlett H, Zhao Y, Joseph J, Devonshire V; UBCMS Clinic Neurologists. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008;79:1368-1374. [PubMed]

2. Held U, Heigenhauser L, Chang C, et al. Predictors of relapse rate in MS clinical trials. Neurology. 2005;65:1769-1773. [PubMed]

3. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis: a multi-centre longitudinal study. Ann Neurol. 1998;43:332-339. [PubMed]

4. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 1999;353:964-969. [PubMed]

5. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study: 2. predictive value of the early clinical course. Brain. 1989;112:1419-1428. [PubMed]

6. Drulovic J, Riise T, Nortvedt M, et al. Self-rated physical health predicts change in disability in multiple sclerosis. Mult Scler. 2008;14:999-1002. [PubMed]

7. Goodin D, Li D, Traboulsee A, et al. The interferon beta-1b 16-year long-term follow-up study: predictive clinical and magnetic resonance imaging. Presented at: The 60th annual meeting of the American Academy of Neurology; April 12-19, 2008; Chicago, IL. Abstract P02.142.

8. Brex PA, Ciccarelli O, O’Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346:158-164. [PubMed]

9. Tintoré M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology. 2006;67:968-972. [PubMed]

10. Gauthier SA, Mandel M, Guttmann CRG, et al. Predicting short-term disability in multiple sclerosis. Neurology. 2007;68:2059-2065. [PubMed]

11. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain. 2008;129:2620-2627. [PubMed]

12. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131:808-817. [PubMed]

13. Minneboo A, Jasperse B, Barkhof F, et al. Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. J Neurol Neurosurg Psychiatry. 2008;79:917-923. [PubMed]

14. Khaleeli Z, Sastre-Garriga J, Ciccarelli O, Miller DH, Thompson AJ. Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2007;78:1076-1082. [PubMed]

15. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology. 2002;59:1412-1420. [PubMed]

16. Summers M, Swanton J, Fernando K, et al. Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry. 2008;79:955-958. [PubMed]

17. Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci. 2001;189:13-21. [PubMed]

18. Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler. 2006;12:143-148. [PubMed]

19. Kragt JJ, Thompson AJ, Montalban X, et al. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS. Neurology. 2008;70:1084-1091. [PubMed]

20. Sastre-Garriga J, Ingle GT, Rovaris M, et al. Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data. Neurology. 2005;65:633-635. [PubMed]

21. Rovaris M, Judica E, Gallo A, et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain. 2006;129:2628-2634. [PubMed]

22. Khaleeli Z, Ciccarelli O, Manfredonia F, et al. Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Ann Neurol. 2008;63:790-793. [PubMed]

23. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult Scler. 2006;12:281-286. [PubMed]

24. Carmona O, Casado V, Moral E, et al. in multiple sclerosis: effect on progression of disability and clinical markers of treatment response. Eur Neurol. 2008;60:279-284. [PubMed]

25. O’Rourke K, Walsh C, Antonelli G, Hutchinson M. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. Mult Scler. 2007;13:336-342. [PubMed]

26. Río J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing remitting multiple sclerosis patients. Mult Scler. 2008;14:479-484. [PubMed]

27. Debouverie M, Vandenberghe N, Morrissey SP, et al. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis. Mult Scler. 2004;10:407-412. [PubMed]

28. Le Page E, Leray E, Taurin G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observation study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008;79:52-56. [PubMed]